ImmunityBio (IBRX) Investors Alert: Important Deadline Approaching for Securities Class Action

Investors who purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX) are being reminded of a critical deadline in an ongoing securities class action lawsuit. The law firm Faruqi & Faruqi, LLP has issued an official notice urging affected investors to take prompt action before the May 26, 2026 deadline to seek lead plaintiff status.

Overview of the Lawsuit Against ImmunityBio

The securities class action lawsuit alleges that ImmunityBio and certain of its executives violated federal securities laws by making false and misleading statements regarding the company’s business operations, regulatory progress, and financial outlook.

According to the complaint, these alleged misrepresentations may have artificially inflated the company’s stock price during the class period. As a result, when the truth became known, investors suffered significant financial losses.

Who Is Affected?

This case is relevant to investors who purchased or otherwise acquired ImmunityBio securities during the designated class period. Individuals or entities that experienced losses may be eligible to participate in the lawsuit and potentially recover damages.

Key Deadline: May 26, 2026

The most critical date for investors to note is May 26, 2026. This is the deadline to apply to the court to be appointed as lead plaintiff in the class action.

The lead plaintiff plays an important role in representing the interests of all class members and helping guide the direction of the litigation. However, investors are not required to serve as lead plaintiff in order to be eligible for any potential recovery.

Why Acting Quickly Matters

Failing to act before the deadline could result in missed opportunities to take a leadership role in the case. While investors may still remain part of the class, they will lose the chance to influence legal strategy and settlement discussions.

Allegations Detailed in the Complaint

The lawsuit outlines several key allegations against ImmunityBio, including:

• Providing misleading statements about the development and regulatory status of its key products
• Failing to disclose material weaknesses in internal controls
• Overstating the company’s ability to meet regulatory requirements
• Issuing overly optimistic projections that lacked a reasonable basis

These alleged actions are said to have misled investors and distorted the company’s true financial and operational condition.

Impact on Stock Price

As negative information began to surface, ImmunityBio’s stock price experienced volatility and declines. Investors who purchased shares at inflated prices may have incurred substantial losses once the market corrected.

Role of Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP is a nationally recognized law firm specializing in securities litigation. The firm has extensive experience representing investors in complex class action cases and has recovered hundreds of millions of dollars for clients.

The firm is actively encouraging investors who suffered losses in ImmunityBio to come forward and discuss their legal rights.

How to Participate

Investors who wish to participate in the lawsuit or seek lead plaintiff status should:

1. Gather documentation of their ImmunityBio stock transactions
2. Contact the law firm before the May 26, 2026 deadline
3. Consult legal counsel to understand their options

Understanding Securities Class Actions

Securities class actions are lawsuits filed on behalf of a group of investors who have suffered similar losses due to alleged misconduct by a company or its executives.

These cases typically involve claims of:

• Fraudulent misrepresentation
• Omission of material facts
• Violation of SEC regulations

Potential Outcomes

If successful, class action lawsuits can result in financial compensation for affected investors. Settlements or court judgments may cover a portion of the losses incurred.

However, outcomes vary depending on the strength of the case, available evidence, and legal proceedings.

Investor Rights and Responsibilities

Investors have the right to seek accountability when companies allegedly violate securities laws. Taking action not only helps individuals recover losses but also promotes transparency and fairness in financial markets.

What Investors Should Do Now

Given the approaching deadline, investors are advised to act promptly. Even if unsure about eligibility, consulting with a legal professional can provide clarity.

Timely action ensures that investors preserve their rights and explore all available legal remedies.

Conclusion

The ongoing securities class action against ImmunityBio represents a significant development for investors affected by the company’s alleged misconduct. With the May 26, 2026 deadline fast approaching, it is crucial for investors to evaluate their positions and consider participating in the case.

Faruqi & Faruqi, LLP continues to investigate claims and advocate for investor rights. Those who suffered financial losses are encouraged to seek legal guidance and take the necessary steps before the deadline expires.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Investors should consult qualified legal counsel to discuss their individual circumstances.

#ImmunityBio #IBRX #InvestorAlert #SecuritiesLawsuit #SlimScan #GrowthStocks #CANSLIM